Superimposed coagulopathic conditions in cirrhosis: infection and endogenous heparinoids, renal failure, and endothelial dysfunction.

[1]  R. Groszmann,et al.  Vascular endothelial dysfunction in cirrhosis. , 2007, Journal of hepatology.

[2]  E. Cholongitas,et al.  The effects of glycosaminoglycans on coagulation: a thromboelastographic study , 2007, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[3]  T. Rabelink,et al.  Endothelial function and dysfunction: testing and clinical relevance. , 2007, Circulation.

[4]  A. Busti,et al.  Evidence-based treatment recommendations for uremic bleeding , 2007, Nature Clinical Practice Nephrology.

[5]  Y. Joo,et al.  Antibiotic Prophylaxis Using Third Generation Cephalosporins Can Reduce the Risk of Early Rebleeding in the First Acute Gastroesophageal Variceal Hemorrhage: A Prospective Randomized Study , 2006, Journal of Korean medical science.

[6]  P. D. de Groot,et al.  Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity , 2006, Hepatology.

[7]  E. Cholongitas,et al.  172 Heparinase I, II and III modified thromboelastography for the detection of different glycosaminoglycans' effect in cirrhotics with bacterial infection , 2006 .

[8]  B. Rehermann,et al.  The liver as an immunological organ , 2006, Hepatology.

[9]  R. Groszmann,et al.  The hyperdynamic circulation of chronic liver diseases: From the patient to the molecule , 2006, Hepatology.

[10]  M. Crowther,et al.  Uremic bleeding: pathophysiology and clinical risk factors. , 2006, Thrombosis research.

[11]  M. Díaz-Ricart,et al.  Uremic platelet dysfunction: past and present. , 2005, Current hematology reports.

[12]  G. Bertino,et al.  Circulating adhesion molecules in patients with virus-related chronic diseases of the liver. , 2005, World journal of gastroenterology.

[13]  D. Vaughan.  PAI‐1 and atherothrombosis , 2005, Journal of thrombosis and haemostasis : JTH.

[14]  A. Burroughs,et al.  Infection, coagulation, and variceal bleeding in cirrhosis , 2005, Gut.

[15]  R. Groszmann,et al.  Portal hypertension: from bedside to bench. , 2005, Journal of clinical gastroenterology.

[16]  J. Rodés,et al.  Sinusoidal endothelial COX-1-derived prostanoids modulate the hepatic vascular tone of cirrhotic rat livers. , 2005, American journal of physiology. Gastrointestinal and liver physiology.

[17]  C. Rodríguez-Ramos,et al.  Adhesion molecules as a prognostic marker of liver cirrhosis , 2005, Scandinavian journal of gastroenterology.

[18]  D. Patch,et al.  Endogenous heparinoids in acute variceal bleeding , 2005, Gut.

[19]  F. Fabris,et al.  Effect of human recombinant erythropoietin on bleeding time, platelet number and function in children with end-stage renal disease maintained by haemodialysis , 1991, Pediatric Nephrology.

[20]  G. Remuzzi,et al.  Platelet dysfunction in renal failure. , 2004, Seminars in thrombosis and hemostasis.

[21]  F. Chang,et al.  Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemorrhage: A randomized trial , 2004, Hepatology.

[22]  A. Burroughs,et al.  Endogenous heparin‐like activity detected by anti‐Xa assay in infected cirrhotic and non‐cirrhotic patients , 2004, Scandinavian journal of gastroenterology.

[23]  A. E. Caballero,et al.  Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease. , 2003, Obesity research.

[24]  J. Rodés,et al.  Cyclooxygenase-1 inhibition corrects endothelial dysfunction in cirrhotic rat livers. , 2003, Journal of hepatology.

[25]  L. Dember,et al.  Thrombosis in End‐Stage Renal Disease , 2003, Seminars in dialysis.

[26]  J. Rodés,et al.  Low doses of isosorbide mononitrate attenuate the postprandial increase in portal pressure in patients with cirrhosis , 2003, Hepatology.

[27]  A. Burroughs,et al.  Bacterial infection in cirrhosis impairs coagulation by a heparin effect: a prospective study. , 2002, Journal of hepatology.

[28]  Filip Braet,et al.  Structural and functional aspects of liver sinusoidal endothelial cell fenestrae: a review , 2002, Comparative hepatology.

[29]  P. D. de Groot,et al.  Haemostatic abnormalities in patients with liver disease. , 2002, Journal of hepatology.

[30]  R. Groszmann,et al.  The paradox of nitric oxide in cirrhosis and portal hypertension: Too much, not enough , 2002, Hepatology.

[31]  E. Mervaala,et al.  Clinically important factors influencing endothelial function. , 2001, Medical Science Monitor.

[32]  P. Angeli,et al.  Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study. , 2001, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[33]  J. Bosch,et al.  Complications of cirrhosis. I. Portal hypertension. , 2000, Journal of hepatology.

[34]  G. Remuzzi,et al.  Uremic bleeding: closing the circle after 30 years of controversies? , 1999, Blood.

[35]  T. Poynard,et al.  Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: A meta‐analysis , 1999, Hepatology.

[36]  B. Davidson,et al.  Hepatic and splanchnic nitric oxide activity in patients with cirrhosis , 1999, Gut.

[37]  A. Burroughs,et al.  Infection and hemostasis in decompensated cirrhosis: A prospective study using thrombelastography , 1999, Hepatology.

[38]  F. Marra,et al.  Complications of cirrhosis: is endothelium guilty? , 1999, Journal of hepatology.

[39]  A. Gadano,et al.  Von Willebrand factor could be an index of endothelial dysfunction in patients with cirrhosis: relationship to degree of liver failure and nitric oxide levels. , 1999, Journal of hepatology.

[40]  A. Burroughs,et al.  Bacterial infection in the pathogenesis of variceal bleeding , 1999, The Lancet.

[41]  R. Ross,et al.  Atherosclerosis is an inflammatory disease. , 1998, American heart journal.

[42]  T. Gupta,et al.  Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats , 1998, Hepatology.

[43]  A. Schafer,et al.  Uremic bleeding: pathogenesis and therapy. , 1998, The American journal of the medical sciences.

[44]  A. Burroughs,et al.  Thrombelastographic changes and early rebleeding in cirrhotic patients with variceal bleeding , 1998, Gut.

[45]  A. Quyyumi.  Endothelial function in health and disease: new insights into the genesis of cardiovascular disease. , 1998, The American journal of medicine.

[46]  C. Sabin,et al.  Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage , 1998, Hepatology.

[47]  D. Rockey,et al.  Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension. , 1998, Gastroenterology.

[48]  G. Torelli,et al.  L-arginine infusion decreases platelet aggregation through an intraplatelet nitric oxide release. , 1997, Thrombosis research.

[49]  D. Riddell,et al.  Apolipoprotein E Inhibits Platelet Aggregation through the L-Arginine:Nitric Oxide Pathway , 1997, The Journal of Biological Chemistry.

[50]  A. Mallat,et al.  Multiple hepatic functions of endothelin-1: physiopathological relevance. , 1996, Journal of hepatology.

[51]  P. Mannucci,et al.  High plasma levels of von Willebrand factor as a marker of endothelial perturbation in cirrhosis: Relationship to endotoxemia , 1996, Hepatology.

[52]  S. Milani,et al.  Endothelin 1 is overexpressed in human cirrhotic liver and exerts multiple effects on activated hepatic stellate cells. , 1996, Gastroenterology.

[53]  M. Hori,et al.  Endothelial dysfunction in the early stage of atherosclerosis precedes appearance of intimal lesions assessable with intravascular ultrasound. , 1996, American heart journal.

[54]  J. Schölmerich,et al.  Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis , 1996, Hepatology.

[55]  E. Masini,et al.  Increased production of nitric oxide by neutrophils and monocytes from cirrhotic patients with ascites and hyperdynamic circulation , 1995, Hepatology.

[56]  J E Tooke,et al.  Microvascular Function in Human Diabetes: A Physiological Perspective , 1995, Diabetes.

[57]  D. Valla,et al.  Prognostic significance of bacterial infection in bleeding cirrhotic patients: a prospective study. , 1995, Gastroenterology.

[58]  S. D. Lee,et al.  Endotoxemia in patients with chronic liver diseases: relationship to severity of liver diseases, presence of esophageal varices, and hyperdynamic circulation. , 1995, Journal of hepatology.

[59]  J. Vane,et al.  Pharmacodynamic profile of prostacyclin. , 1995, The American journal of cardiology.

[60]  J. Gratton,et al.  Characterization of Endothelin Receptors and Endothelin‐Converting Enzyme Activity in the Rabbit Lung , 1995, Journal of cardiovascular pharmacology.

[61]  M. Gawaz,et al.  Impaired function of platelet membrane glycoprotein IIb-IIIa in end-stage renal disease. , 1994, Journal of the American Society of Nephrology : JASN.

[62]  G. Remuzzi,et al.  Reversible activation defect of the platelet glycoprotein IIb-IIIa complex in patients with uremia. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[63]  J. White,et al.  Abnormal cytoskeletal assembly in platelets from uremic patients. , 1993, American Journal of Pathology.

[64]  G. Remuzzi,et al.  Enhanced nitric oxide synthesis in uremia: implications for platelet dysfunction and dialysis hypotension. , 1993, Kidney international.

[65]  E. Strauss,et al.  A prospective study of bacterial infections in patients with cirrhosis. , 1993, Journal of hepatology.

[66]  G. Escolar,et al.  Recombinant human erythropoietin treatment improves platelet function in uremic patients. , 1992, Kidney international.

[67]  C. Cordova,et al.  Clotting abnormalities in chronic liver disease. , 1992, Digestive diseases.

[68]  F. Leebeek,et al.  A shift in balance between profibrinolytic and antifibrinolytic factors causes enhanced fibrinolysis in cirrhosis. , 1991, Gastroenterology.

[69]  G. Escolar,et al.  Uremic platelets have a functional defect affecting the interaction of von Willebrand factor with glycoprotein IIb-IIIa. , 1990, Blood.

[70]  J. Vermylen,et al.  Recombinant Human Erythropoietin Increases Blood Pressure, Platelet Aggregability and Platelet Free Calcium Mobilisation in Uraemic Children: A Possible Link? , 1990, Thrombosis and Haemostasis.

[71]  J. Sixma,et al.  High von Willebrand factor concentration compensates a relative adhesion defect in uremic blood. , 1990, Blood.

[72]  G. Remuzzi.  BLEEDING IN RENAL FAILURE , 1988, The Lancet.

[73]  C. Ponticelli,et al.  IMPROVEMENT IN THE HAEMOSTATIC DEFECT OF URAEMIA AFTER TREATMENT WITH RECOMBINANT HUMAN ERYTHROPOIETIN , 1987, The Lancet.

[74]  S. Moncada,et al.  ENDOGENOUS NITRIC OXIDE INHIBITS HUMAN PLATELET ADHESION TO VASCULAR ENDOTHELIUM , 1987, The Lancet.

[75]  G. Bleichner,et al.  Frequency of infections in cirrhotic patients presenting with acute gastrointestinal haemorrhage , 1986, The British journal of surgery.

[76]  G. Di Minno,et al.  Platelet dysfunction in uremia. II. Correction by arachidonic acid of the impaired exposure of fibrinogen receptors by adenosine diphosphate or collagen. , 1986, The Journal of laboratory and clinical medicine.

[77]  G. Escolar,et al.  Defective platelet adhesion on vessel subendothelium in uremic patients , 1986 .

[78]  G. Di Minno,et al.  Platelet dysfunction in uremia. Multifaceted defect partially corrected by dialysis. , 1985, The American journal of medicine.

[79]  G. Remuzzi,et al.  Coagulation abnormalities in uremia. , 1985, Seminars in nephrology.

[80]  D. Durand,et al.  Low haematocrit and prolonged bleeding time in uraemic patients: effect of red cell transfusions , 1985, British journal of haematology.

[81]  V. Arroyo,et al.  Reticuloendothelial System Phagocytic Activity in Cirrhosis and Its Relation to Bacterial Infections and Prognosis , 1984, Hepatology.

[82]  G. Remuzzi,et al.  Reduced platelet thromboxane formation in uremia. Evidence for a functional cyclooxygenase defect. , 1983, The Journal of clinical investigation.

[83]  G. Remuzzi,et al.  URAEMIC BLEEDING: ROLE OF ANAEMIA AND BENEFICIAL EFFECT OF RED CELL TRANSFUSIONS , 1982, The Lancet.

[84]  G. Eknoyan,et al.  Biochemical Abnormalities of Platelets in Renal Failure , 1981 .

[85]  G. Remuzzi,et al.  Bleeding in renal failure: altered platelet function in chronic uraemia only partially corrected by haemodialysis. , 1978, Nephron.

[86]  A. Teien.  Heparin Elimination in Patients with Liver Cirrhosis , 1977, Thrombosis and Haemostasis.

[87]  A. Montecinos,et al.  [Platelet dysfunction in uremia]. , 1973, Revista medica de Chile.

[88]  S. F. Rabiner.  THE EFFECT OF DIALYSIS ON PLATELET FUNCTION OF PATIENTS WITH RENAL FAILURE , 1972, Annals of the New York Academy of Sciences.

[89]  P. Castaldi,et al.  Uraemic bleeding: a reversible platelet defect corrected by dialysis. , 1967, The Quarterly journal of medicine.

[90]  Cole Pv.  Treatment of Reflux Oesophagitis , 1964 .